Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
CD4+ Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice
Yasuto Ikehara, … , Masaru Taniguchi, Seiyo Ikeda
Yasuto Ikehara, … , Masaru Taniguchi, Seiyo Ikeda
Published June 15, 2000
Citation Information: J Clin Invest. 2000;105(12):1761-1767. https://doi.org/10.1172/JCI8922.
View: Text | PDF
Article

CD4+ Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice

  • Text
  • PDF
Abstract

Pancreatic islet transplantation represents a potential treatment for insulin-dependent diabetes mellitus. However, the precise cellular and molecular mechanisms of the immune reactions against allogeneic and xenogeneic transplanted islets remain unclear. Here, we demonstrate that CD4+ Vα14 natural killer T (NKT) cells, a recently identified lymphoid cell lineage, are required for the acceptance of intrahepatic rat islet xenografts. An anti-CD4 mAb, administrated after transplantation, allowed islet xenografts to be accepted by C57BL/6 mice, with no need for immunosuppressive drugs. The dose of anti-CD4 mAb was critical, and the beneficial effect appeared to be associated with the reappearance of CD4+ NKT cells at around 14 days after transplantation. Interestingly, rat islet xenografts were rejected, despite the anti-CD4 mAb treatment, in Vα14 NKT cell–deficient mice, which exhibit the normal complement of conventional lymphoid cells; adoptive transfer of Vα14 NKT cells into Vα14 NKT cell–deficient mice restored the acceptance of rat islet xenografts. In addition, rat islet xenografts were accepted by Vα14 NKT mice having only Vα14 NKT cells and no other lymphoid cells. These results indicate that Vα14 NKT cells play a crucial role in the acceptance of rat islet xenografts in mice treated with anti-CD4 antibody, probably by serving as immunosuppressive regulatory cells.

Authors

Yasuto Ikehara, Yohichi Yasunami, Shohta Kodama, Takanobu Maki, Masahiko Nakano, Toshinori Nakayama, Masaru Taniguchi, Seiyo Ikeda

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Light photomicrographs of transplanted islet grafts in the liver. (a) An...
Light photomicrographs of transplanted islet grafts in the liver. (a) An intact islet with well-granulated β cells observed in the liver of a mouse treated with 50 μg of anti-CD4 mAb. The sample was prepared 60 days after transplantation. (b) A representative islet xenograft in the liver of a mouse treated with 200 μg of anti-CD4 mAb. HE, hematoxylin and eosin staining; AF, aldehyde and fuchsin staining. ×160.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts